Department of Pharmacy, Peking University First Hospital, Beijing, 100034, China.
Department of Cardiology, Peking University First Hospital, Beijing, 100034, China.
Eur J Clin Pharmacol. 2021 Apr;77(4):569-581. doi: 10.1007/s00228-020-03029-1. Epub 2020 Nov 4.
A meta-analysis was performed to evaluate the correlation between single-nucleotide polymorphisms (SNPs) and risk of statin-induced myopathy (SIM).
We retrieved the studies published on SIM until April 2019 from the PubMed, Embase, and Cochrane Library databases. We collected data from 32 studies that analyzed 10 SNPs in five genes and included 21,692 individuals and nine statins.
The analysis of the heterozygous (p = 0.017), homozygous (p = 0.002), dominant (p = 0.005), and recessive models (p = 0.009) of SLCO1B1 rs4149056 showed that this SNP increases the risk of SIM. Conversely, heterozygous (p = 0.048) and dominant models (p = 0.030) of SLCO1B1 rs4363657 demonstrated that this SNP is associated with a reduced risk of SIM. Moreover, an increased risk of SIM was predicted for carriers of the rs4149056 C allele among simvastatin-treated patients, whereas carriers of the GATM rs9806699 A allele among rosuvastatin-treated patients had a lower risk of SIM.
The meta-analysis revealed that the rs4149056 and rs4363657 SNPs in SLCO1B1 and the rs9806699 SNP in GATM are correlated with the risk of SIM.
进行了一项荟萃分析,以评估单核苷酸多态性 (SNPs) 与他汀类药物诱导的肌病 (SIM) 风险之间的相关性。
我们从 PubMed、Embase 和 Cochrane Library 数据库中检索了截至 2019 年 4 月发表的关于 SIM 的研究。我们从分析了五个基因中的 10 个 SNPs 并纳入了 21692 名个体和九种他汀类药物的 32 项研究中收集了数据。
SLCO1B1 rs4149056 的杂合子(p=0.017)、纯合子(p=0.002)、显性(p=0.005)和隐性模型(p=0.009)分析表明,该 SNP 增加了 SIM 的风险。相反,SLCO1B1 rs4363657 的杂合子(p=0.048)和显性模型(p=0.030)表明,该 SNP 与 SIM 风险降低相关。此外,在辛伐他汀治疗患者中,携带 SLCO1B1 rs4149056 C 等位基因的患者发生 SIM 的风险增加,而在接受瑞舒伐他汀治疗的患者中,携带 GATM rs9806699 A 等位基因的患者发生 SIM 的风险降低。
荟萃分析表明,SLCO1B1 中的 rs4149056 和 rs4363657 SNPs 以及 GATM 中的 rs9806699 SNP 与 SIM 风险相关。